L-citrulline Supplementation & Cold Exposure
Completed · Phase 1/Phase 2
Conditions studied: Hypertension
In brief
Cardiovascular disease (CVD) is considered the primary cause of death in the developed world. Large scale epidemiological studies indicate that prevalence of hypertension along with adverse cardiovascular events peak during the winter months. Moreover, during the winter months outdoor activities and physical stressors such as exercise have been associated with higher cardiovascular mortality when compared to other periods of the year. Although low environmental temperatures have been implicated as the triggering factor for cardiovascular complications, the mechanisms on how cold exposure increase cardiovascular morbidity and mortality remain to be elucidated. However, new research suggests that cold exposure may induce increases in cardiac sympathetic activity, endothelial damage and increased arterial stiffness of central arteries. Cardiovascular drugs including antihypertensive pharmacological agents seem to be inefficient to provide appropriate therapeutic effects during cold exposure. Therefore, it is imperative to propose alternative non-pharmacological therapies intended to prevent the detrimental effects of low environmental temperatures on cardiovascular function. Recently, oral supplementation of the amino acid L-citrulline has been proposed as an effective therapeutic adjuvant for the treatment of hypertension. L-citrulline is known to enhance the bioavailability of L-arginine levels and increase endothelial nitric oxide (NO) production, one of the main modulators of vascular tone and blood pressure (BP). L-citrulline supplementation has been shown to increase endothelial function, reduce BP, and ameliorate endothelial oxidative damage without any adverse effects. Our group has demonstrated that L-citrulline supplementation attenuates the BP response to cold exposure (the cold pressor test, CPT). These studies suggest that L-citrulline supplementation may be a feasible therapeutic aid in order to prevent cardiovascular complications associated with cold exposure. However the potential cardioprotective effects of L-citrulline supplementation during cold exposure with exercise have yet to be evaluated. It is hypothesized that L-citrulline supplementation would reduce arterial stiffness and blood pressure (BP) responses to physiological stress (cold exposure). This study may lead to the development of an adjunct therapy for the prevention and management of cardiovascular adverse events that are particularly increased during the winter months.
Key facts
- Study ID
- NCT01462591
- Run by
- Florida State University
- People needed
- 16
- Starts
- 2011-05-01
- Expected to finish
- 2012-05-01
- Last updated by the study team
- 2014-08-05
Who can join
Age: 18 and older, up to 35. Sex: male. Healthy volunteers: accepted.
You may qualify if…
- Men
- Blood pressure lower than 140/90mmHg
- Age 18 to 35 years
- BMI 20-39 kg/m2
You may not qualify if…
- Blood Pressure >160/100 mmHg
- Asthma
- Glaucoma
- Herpes simplex
- Uncontrolled diabetes
- Neurological disease
- Cardiovascular disease
- Inflammatory disease
- Kidney disease
- Hormone replacement therapy (HRT)
- Amino acid/vitamin supplementation\\
- Corticosteroids or non-steroidal anti-inflammatory drugs
- Any drug known to affect BP or heart rate
- Glycemic control drugs
- Lipids reducing drugs
- Participants should not consume > 12 alcoholic drink/week
- Smokers
- Regular Exercisers (>1.5 hour/week).
Where it is running
- FSU College of Human Sciences — Tallahassee, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.